Category: FEM news

Femtogenix Presents Data at AACR Annual Meeting 2018 Showing High Potency of Its New Generation DNA-Binding Payloads in Antibody Drug Conjugates

WELWYN GARDEN CITY, United Kingdom, and CHICAGO, April 12, 2018 /PRNewswire/ — Femtogenix, Ltd, a UK biotechnology company pioneering the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, today announced it will present data highlighting the high potency of its new generation of DNA binders for ADCs at the American Association for Cancer Research… Read more »

Femtogenix to present a plenary session entitled “Pyridinobenzodiazepines: A Novel Class of ADC Payloads” at World ADC San Diego 2017

Professor David Thurston, Chief Scientific Officer of Femtogenix Ltd will present data on a new class of ADC payload developed by the company. The pyridinobenzodiazepines are a sequence-specific, DNA mono-alkylating class of payload. The presentation will illustrate a payload mechanism of action new to the ADC field, potent in vitro and in vivo activity, ease… Read more »

Femtogenix traces the history of the pyrrolobenzodiazepines from discovery to use in ADCs in Angewandte Chemie review article

Femtogenix has published a review article on the development of PBD-containing Antibody-Drug Conjugates. The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases. The first example of a PBD monomer, the natural product anthramycin, was discovered in… Read more »

Femtogenix uses proprietary molecular dynamics simulation techniques to evaluate DNA sequence-selectivity of G-A cross-linking PBD-duocarmycin dimers

Femtogenix has published a research article on the use of molecular dynamics simulations to evaluate DNA sequence-selectivity of G-A cross-linking PBD-duocarmycin dimers. The pyrrolobenzodiazepine (PBD) and duocarmycin families (CPI and CBI units) are DNA-interactive agents that covalently bond to guanine (G) and adenine (A) bases in the minor groove. These moieties have been joined together… Read more »

Prof. David Thurston Receives International Award for “Individual Input to the Field 2015/2016” at the World ADC Awards Event in San Diego

Prof. David Thurston, a leader in the field of antibody-drug conjugates (ADCs), has been acknowledged for his contribution to the area over the past 12 months and previous decades. His academic group synthesized the first C8/C8’-linked pyrrolobenzodiazepine (PBD) dimer in the early 1990s, and PBD dimers are now recognized as one of the most important… Read more »

Femtogenix illustrates the potential of pyrrolobenzodiazepine (PBD) monomeric conjugates and dimers to bind to terminal guanine bases of DNA

Femtogenix co‑authored a research article on 7th April 2016 entitled ‘Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments’. PBD molecules were traditionally thought to require a DNA triplet (e.g., 5’‑AGA‑3’) to bind to DNA. Through HPLC, MS‑MS and molecular dynamics simulation experiments, researchers demonstrated that PBD dimers and… Read more »

King’s College London and RCT Establish New Anticancer Drug Discovery Company

A new company, Femtogenix Ltd, has been formed by King’s College London and Research Corporation Technologies (RCT) of Tucson, Arizona (USA), with RCT also providing Series A funding for the venture. The new company is based on the work of David Thurston, Professor of Drug Discovery, and his colleagues Dr Miraz Rahman and Dr Paul… Read more »